Journal of Medicinal Chemistry · 2017 · 41 citations · 37 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationStructure-activity RelationshipsAmyloid FormationFragment-based Drug DesignFragment-based OptimizationLigand BindingPotency OptimizationTau PathologyAlzheimer Disease Tau PathologyFragment-based DiscoveryFragment-based SimilarityPet TracersPhysicochemical PropertiesQuinoline ChemistrySelectivityTau Aggregation
A mini-HTS on 4000 compounds selected using 2D fragment-based similarity and 3D pharmacophoric and shape similarity to known selective tau aggregate binders identified N-(6-methylpyridin-2-yl)quinolin-2-amine 10 as a novel potent binder to human AD aggregated tau with modest selectivity versus aggregated β-amyloid (Aβ). Initial medicinal chemistry efforts identified key elements for potency and selectivity, as well as suitable positions for radiofluorination, leading to a first generation of fluoroalkyl-substituted quinoline tau binding ligands with suboptimal physicochemical properties. Further optimization toward a more optimal pharmacokinetic profile led to the discovery of 1,5-naphthyridine 75, a potent and selective tau aggregate binder with potential as a tau PET tracer.
37
Extended-Connectivity Fingerprints
David Rogers, Mathew Hahn · Journal of Chemical Information and Modeling · 2010 · 7.6K citations
Diagnosis of Alzheimer's Disease
Zaven S. Khachaturian · Archives of Neurology · 1985 · 2.5K citations
Medicine, Neurology, Psychiatry +13
PET Imaging of Tau Deposition in the Aging Human Brain
Michael Schöll, Samuel N. Lockhart, Daniel R. Schonhaut et al. · Neuron · 2016 · 1.2K citations · Full text